Prognostic Modeling for Bone Sarcomas Based on a Large Prospective Cohort From a Tertiary Care Cancer Center in India.

IF 3 Q2 ONCOLOGY JCO Global Oncology Pub Date : 2025-02-01 Epub Date: 2025-02-06 DOI:10.1200/GO.24.00142
Jyoti Bajpai, Laboni Sarkar, Sushmita Rath, Akash Pawar, Arun Chandrashekharan, Goutam Panda, Dharmpal Jakar, Jaya Ghosh, Siddhartha Laskar, Bharat Rekhi, Nehal Khanna, Jifmi Jose, Mukta Ramdawar, Nilendu Purandare, Prabhat Bhargava, Nivedita Chakrabarty, Kunal Gala, Yogesh Kembhavi, Venkatesh Rangarajan, Shripad Banavali, Sudeep Gupta
{"title":"Prognostic Modeling for Bone Sarcomas Based on a Large Prospective Cohort From a Tertiary Care Cancer Center in India.","authors":"Jyoti Bajpai, Laboni Sarkar, Sushmita Rath, Akash Pawar, Arun Chandrashekharan, Goutam Panda, Dharmpal Jakar, Jaya Ghosh, Siddhartha Laskar, Bharat Rekhi, Nehal Khanna, Jifmi Jose, Mukta Ramdawar, Nilendu Purandare, Prabhat Bhargava, Nivedita Chakrabarty, Kunal Gala, Yogesh Kembhavi, Venkatesh Rangarajan, Shripad Banavali, Sudeep Gupta","doi":"10.1200/GO.24.00142","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Outcomes of adolescents and young adults (AYA) with bone sarcomas including osteosarcoma (OGS) and Ewing sarcoma (ES) are affected by various factors including inadvertent previous treatment and poor compliance. We aimed to develop a risk-scoring system derived and validated at a tertiary care cancer center in India.</p><p><strong>Methods: </strong>All AYA OGS and ES cases treated at our institute with OGS-12 and Ewing's family of tumors-2001 (EFT-2001) protocols from 2011 to 2021 and 2013 to 2018, respectively, were prospectively analyzed. Weighted scores provided to each prognostic variable on the basis of approximate ratios of the beta coefficients of each factor in the multivariable model were summated to divide patients into three clinically discriminatory risk groups, validated by applying separately to derivation, validation, and whole cohorts.</p><p><strong>Results: </strong>Among 606 (81.0%) of 748 AYA with nonmetastatic OGS, significant factors included in the prognostic model were failure to complete protocol (hazard ratio [HR], 2.65), previous treatment (HR, 2.93), necrosis <90% (HR, 1.63), joint involvement (HR, 2.0), and serum alkaline phosphatase >median (204 U/L; HR, 1.63). Of 104 (39.5%) of 263 AYA with ES, significant factors were failure to complete protocol (HR, 2.84), previous treatment (HR, 6.37), necrosis <100% (HR, 8.73), and tumor size >8 cm (HR, 2.64). For 142 (38.8%) of 366 AYA with metastatic OGS, significant factors were failure to complete protocol (HR, 5.29), metastases not amenable to local treatment (HR, 1.96), necrosis <90% (HR, 1.96), and >10 metastases (HR, 2.44). For 38 (43.6%) of 82 AYA with metastatic extremity ES, significant factors were failure to complete protocol (HR, 3.88) and metastases not amenable to local treatment (HR, 10.6).</p><p><strong>Conclusion: </strong>We developed simple, effective prognostic models for AYA with bone sarcomas with specific potential relevance for low- and middle-income countries.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400142"},"PeriodicalIF":3.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11892611/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCO Global Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1200/GO.24.00142","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/6 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Outcomes of adolescents and young adults (AYA) with bone sarcomas including osteosarcoma (OGS) and Ewing sarcoma (ES) are affected by various factors including inadvertent previous treatment and poor compliance. We aimed to develop a risk-scoring system derived and validated at a tertiary care cancer center in India.

Methods: All AYA OGS and ES cases treated at our institute with OGS-12 and Ewing's family of tumors-2001 (EFT-2001) protocols from 2011 to 2021 and 2013 to 2018, respectively, were prospectively analyzed. Weighted scores provided to each prognostic variable on the basis of approximate ratios of the beta coefficients of each factor in the multivariable model were summated to divide patients into three clinically discriminatory risk groups, validated by applying separately to derivation, validation, and whole cohorts.

Results: Among 606 (81.0%) of 748 AYA with nonmetastatic OGS, significant factors included in the prognostic model were failure to complete protocol (hazard ratio [HR], 2.65), previous treatment (HR, 2.93), necrosis <90% (HR, 1.63), joint involvement (HR, 2.0), and serum alkaline phosphatase >median (204 U/L; HR, 1.63). Of 104 (39.5%) of 263 AYA with ES, significant factors were failure to complete protocol (HR, 2.84), previous treatment (HR, 6.37), necrosis <100% (HR, 8.73), and tumor size >8 cm (HR, 2.64). For 142 (38.8%) of 366 AYA with metastatic OGS, significant factors were failure to complete protocol (HR, 5.29), metastases not amenable to local treatment (HR, 1.96), necrosis <90% (HR, 1.96), and >10 metastases (HR, 2.44). For 38 (43.6%) of 82 AYA with metastatic extremity ES, significant factors were failure to complete protocol (HR, 3.88) and metastases not amenable to local treatment (HR, 10.6).

Conclusion: We developed simple, effective prognostic models for AYA with bone sarcomas with specific potential relevance for low- and middle-income countries.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
基于印度三级护理癌症中心的大型前瞻性队列骨肉瘤的预后建模
目的:骨肉瘤包括骨肉瘤(OGS)和尤文氏肉瘤(ES)的青少年和青壮年(AYA)的预后受到多种因素的影响,包括先前的治疗疏忽和依从性差。我们的目标是开发一种风险评分系统,并在印度的三级护理癌症中心得到验证。方法:对2011年至2021年和2013年至2018年分别采用OGS-12和Ewing肿瘤家族-2001 (EFT-2001)方案治疗的所有AYA OGS和ES病例进行前瞻性分析。根据多变量模型中每个因素的beta系数的近似比值,对每个预后变量的加权评分进行求和,将患者分为三个临床歧视性风险组,分别应用推导、验证和全队列进行验证。结果:在748例AYA合并非转移性OGS的606例(81.0%)患者中,未完成治疗方案(风险比[HR], 2.65)、既往治疗(HR, 2.93)、中位坏死(204 U/L;人力资源,1.63)。在263例AYA合并ES的104例(39.5%)中,显著因素为未能完成方案(HR, 2.84)、既往治疗(HR, 6.37)、坏死8 cm (HR, 2.64)。366例AYA中有142例(38.8%)合并转移性OGS,主要因素是未能完成治疗方案(HR, 5.29),转移不适合局部治疗(HR, 1.96),坏死10例转移(HR, 2.44)。82例AYA中有38例(43.6%)伴有转移性肢体ES,重要因素是未能完成治疗方案(HR, 3.88)和转移不适合局部治疗(HR, 10.6)。结论:我们开发了简单、有效的骨肉瘤AYA预后模型,对低收入和中等收入国家具有特殊的潜在相关性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
JCO Global Oncology
JCO Global Oncology Medicine-Oncology
CiteScore
6.70
自引率
6.70%
发文量
310
审稿时长
7 weeks
期刊最新文献
Evaluating Risk Factors for Early Mortality in Adult ALL in Brazil. Chemotherapy Medications in Sub-Saharan Africa: Availability, Pricing, Affordability, and Predictors of Quality. National Trends in Early-Onset Colorectal Cancer: Incidence and Challenges in the Republic of Ireland. Global Trials, Local Relevance: A Scientific and Regulatory Framework for Regional Enrollment in Cancer Drug Development. Gastric Cancer Mortality-to-Incidence Ratios in Latin America and the Caribbean: A Machine Learning Analysis of Socioeconomic and Clinical Research Predictors.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1